Study ID: CA43-IM032-041 for Plaque Psoriasis

Summary

Plaque Psoriasis

This study is testing an investigational drug called BMS-986322 (the “study drug”) in adults with plaque psoriasis. The purpose of the study is to learn whether the study drug is safe and effective at different dose levels.


Study design
If you qualify and choose to participate in this study, you will:


– Take either the study drug (at one of three dose levels) or placebo* for 12 weeks
– Visit the study doctor 8 times for tests and procedures to assess your health and
your plaque psoriasis.
A computer will assign you at random (by chance) to a study group. You will have a 3 in 4 (75%) chance of being in a group that takes the study drug; you will have a 1 in 4 (25%) chance of being in the group that takes only placebo. You will not know which group you are in; the study doctor and staff also will not know.


Study periods
The study is split into three main stages (also known as “study periods”). These are briefly described here. The study doctor will explain them in more detail.


1. Screening (informed consent** followed by screening tests and procedures to find out if you qualify to participate in the study)
2. Study treatment (12 weeks of taking either the study drug or placebo)
3. Follow-up (final visit 30 days after study treatment ends)

* A placebo is a substance that looks like the study drug but contains no active
ingredients. Placebos help us make sure that any changes are due to the study drug and not another reason.
** During informed consent, the study will be explained to you. You will be able to ask any questions you may have about the study.

If you want to take part in the study, you will sign the informed consent form before any screening tests begin.

Study Details

Study Name Age Requirements Length of Study Type of Treatment
CA43-IM032-041
18-70
16 Weeks. (9 visits to the clinic)
Oral

This study is testing an investigational drug called BMS-986322 (the “study drug”) in adults with plaque psoriasis. The purpose of the study is to learn whether the study drug is safe and effective at different dose levels.


Study design
If you qualify and choose to participate in this study, you will:


– Take either the study drug (at one of three dose levels) or placebo* for 12 weeks
– Visit the study doctor 8 times for tests and procedures to assess your health and
your plaque psoriasis.
A computer will assign you at random (by chance) to a study group. You will have a 3 in 4 (75%) chance of being in a group that takes the study drug; you will have a 1 in 4 (25%) chance of being in the group that takes only placebo. You will not know which group you are in; the study doctor and staff also will not know.


Study periods
The study is split into three main stages (also known as “study periods”). These are briefly described here. The study doctor will explain them in more detail.


1. Screening (informed consent** followed by screening tests and procedures to find out if you qualify to participate in the study)
2. Study treatment (12 weeks of taking either the study drug or placebo)
3. Follow-up (final visit 30 days after study treatment ends)

* A placebo is a substance that looks like the study drug but contains no active
ingredients. Placebos help us make sure that any changes are due to the study drug and not another reason.
** During informed consent, the study will be explained to you. You will be able to ask any questions you may have about the study.

If you want to take part in the study, you will sign the informed consent form before any screening tests begin.

Contact us about joining the trial

To be eligible for this trial, applicants MUST have a skin condition. We DO NOT accept volunteers who do not have a skin disease.

Fill out this form to get in touch or call our clinical trial line at #(289)-763-8666. We will contact you in 1-2 business days regarding your application to participate in the trial.

Privacy Policy for SimcoDerm Clinical Trials

Your privacy is important to us, and we take the protection of your personal health information (PHI) seriously. This policy explains how we collect, use, and protect your information.

We collect information directly from you, including your name, contact details, health information, and treatment history.

We use your information to determine eligibility for clinical trials, manage appointments, and communicate with you about your participation in clinical trials.

Data Protection:

Your information is stored securely and is only accessible by authorized personnel. We use data encryption, conduct security audits, and implement strict access controls to ensure the protection of your personal information.

You have the right to access, amend, or request the deletion of your health records. To exercise these rights, send a request to our clinical trial support team.